Biohaven (BHVN) Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biohaven in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BHVN shares.
View BHVN analyst ratings or view top-rated stocks.

6 brokerages have issued 1-year target prices for Biohaven's shares. Their BHVN share price forecasts range from $21.00 to $31.00. On average, they expect the company's stock price to reach $25.25 in the next twelve months. This suggests a possible upside of 43.1% from the stock's current price.
View analysts price targets for BHVN or view top-rated stocks among Wall Street analysts.

Biohaven's stock was trading at $13.88 at the beginning of the year. Since then, BHVN stock has increased by 27.2% and is now trading at $17.65.
View the best growth stocks for 2023 here.

Biohaven saw a increase in short interest during the month of August. As of August 15th, there was short interest totaling 5,520,000 shares, an increase of 12.7% from the July 31st total of 4,900,000 shares. Based on an average trading volume of 1,130,000 shares, the days-to-cover ratio is currently 4.9 days. Currently, 9.5% of the shares of the company are sold short.
View Biohaven's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our BHVN earnings forecast.

Biohaven Ltd. (NYSE:BHVN) issued its quarterly earnings data on Monday, July, 31st. The company reported ($1.32) EPS for the quarter, missing analysts' consensus estimates of ($1.18) by $0.14.

ETFs with the largest weight of Biohaven (NYSE:BHVN) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN).Invesco Dorsey Wright Healthcare Momentum ETF (PTH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).

(BHVN) raised $124 million in an IPO on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Biohaven trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Biohaven's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.49%), Suvretta Capital Management LLC (5.66%), State Street Corp (4.20%), Holocene Advisors LP (3.02%), Geode Capital Management LLC (1.76%) and Point72 Asset Management L.P. (1.71%). Insiders that own company stock include Declan Doogan, Elyse Stock, George C Clark, Gregory Bailey, James Engelhart, John W Childs, Julia P Gregory, Kimberly Gentile, Matthew Buten, Vlad Coric and William A Jones Jr.
View institutional ownership trends.

Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BHVN stock can currently be purchased for approximately $17.65.

Biohaven (NYSE:BHVN) has a market capitalization of $1.21 billion and generates $462.51 million in revenue each year. The company earns $-570,280,000.00 in net income (profit) each year or ($7.42) on an earnings per share basis.

The company employs 928 workers across the globe.

Biohaven's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The official website for the company is www.biohavenpharma.com. The company can be reached via phone at 203-404-0410 or via email at jennifer.porcelli@biohavenpharma.com.